News

Studies explain gene’s role in thrombosis, hemostasis


 

Thrombus

Credit: Kevin MacKenzie

Two preclinical studies provide new insight into the activity of STXBP5, a gene that has been linked to changes in von Willebrand factor (VWF).

One research group found evidence suggesting that STXBP5 regulates endothelial exocytosis and thrombosis.

Another group’s work indicated that STXBP5 is required for normal arterial hemostasis, as it contributes to platelet packaging and secretion.

Both studies appear in The Journal of Clinical Investigation.

Charles Lowenstein, MD, of the University of Rochester in New York, and his colleagues began their research with the theory that STXBP5 inhibits endothelial cell exocytosis.

The group found that STXBP5 is expressed in human endothelial cells, and reducing STXBP5 increases exocytosis of VWF and P-selectin.

STXBP5-knockout mice had higher levels of VWF in their plasma, increased P-selectin translocation, and more platelet-endothelial interactions. This suggests that defective STXBP5 is a risk factor for thrombosis.

However, STXBP5-knockout mice also exhibited prolonged bleeding and impaired thrombosis. They had defects in platelet secretion and activation as well.

Sidney (Wally) Whiteheart, PhD, of the University of Kentucky in Lexington, and his colleagues helped to explain these findings with their research.

The group showed that platelets lacking SXTBP5 failed to function correctly, and SXTBP5 was required for platelets to assist in normal clot formation. This suggests STXBP5 plays different roles in endothelial cells and platelets.

Specifically, the researchers found that STXBP5 interacts with core secretion machinery complexes and the platelet cytoskeleton.

And platelets from STXBP5-knockout mice exhibited defects in granule secretion. These platelets had altered granule cargo levels, despite having normal morphology and granule numbers.

Like Dr Lowenstein’s group, Dr Whiteheart and his colleagues observed dramatic bleeding and defective hemostasis in STXBP5-knockout mice. Transplant experiments suggested these defects were due to a loss of STXBP5 in bone marrow-derived cells.

Recommended Reading

Bivalirudin bests heparin in BRIGHT trial
MDedge Hematology and Oncology
Shorter duration of DAPT appears safe
MDedge Hematology and Oncology
Longer duration of triple therapy confers no benefit, trial suggests
MDedge Hematology and Oncology
Most VTE therapies produce comparable results, analysis suggests
MDedge Hematology and Oncology
FDA approves treatment for kids with hemophilia B
MDedge Hematology and Oncology
Hemostats may decrease costs, use of resources
MDedge Hematology and Oncology
Heparin lot recalled due to particulate
MDedge Hematology and Oncology
NICE recommends eculizumab for aHUS despite cost
MDedge Hematology and Oncology
Synthetic platelets can augment natural clotting
MDedge Hematology and Oncology
Method may fight inhibitor formation in hemophilia A
MDedge Hematology and Oncology